ANIP — ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $227.8 million, up 53.6% year-over-year.
• Rare Disease Revenue: $118.5 million, a 109.9% increase, with Cortrophin Gel contributing $101.9 million (up 93.8%).
• Adjusted EBITDA: $59.6 million, a 69.8% increase year-over-year.
• Adjusted EPS: $2.04, compared to $1.34 in the prior year.
• Cash Position: Unrestricted cash increased to $262.6 million from $217.8 million in Q2 2025.
• Debt: $633.1 million in outstanding debt, with a gross leverage of 3x and net leverage of 1.7x adjusted EBITDA.

2. Strategic Updates and Business Highlights

• Cortrophin Gel: Significant growth driven by increased new patient starts and the launch of a prefilled syringe, enhancing patient convenience.
• Generics Business: Strong performance attributed to a successful partnered generic launch, with expected full-year growth in the low 20% range.
• ILUVIEN: Sales were impacted by reduced Medicare access and a transition to new indications, but the company is optimistic about future growth through enhanced marketing and education efforts.
• Sales Force Expansion: Increased sales team by approximately one-third to drive growth across specialties, particularly in rheumatology, nephrology, and ophthalmology.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Raised to $854 million to $873 million, reflecting a year-over-year growth of 39% to 42%.
• Cortrophin Gel Revenue: Expected to reach $347 million to $352 million, a growth of 75% to 78%.
• Adjusted EBITDA Guidance: Revised to $221 million to $228 million, indicating growth of 42% to 46%.
• ILUVIEN and YUTIQ Revenue: Expected to be $73 million to $77 million, down from previous guidance due to ongoing Medicare challenges.

4. Bad News, Challenges, or Points of Concern

• ILUVIEN Sales Decline: Sales were negatively impacted by ongoing access issues for Medicare patients and a shift in utilization patterns.
• Generics Competition: Anticipated sequential decline in Generics revenue due to new competitive entrants in the market.
• Cortrophin Growth Sustainability: Future growth may face challenges as the Medicare Part D redesign creates tough year-over-year comparisons, necessitating organic growth strategies.
• Market Access Issues: Continued difficulties in securing co-pay support for Medicare patients, particularly affecting ILUVIEN.

5. Notable Q&A Insights

• Cortrophin Growth Drivers: Management emphasized the strong underlying demand and the potential for expanding prescriber base, particularly among those unfamiliar with ACTH therapies.
• Sales Force Effectiveness: The expansion of the sales force has shown immediate positive returns, indicating the market's sensitivity to promotion.
• Generic Product Strategy: The recent partnered generic launch was successful, but competition is expected to impact future revenue.
• Long-term Outlook for Cortrophin: Management expressed confidence in the long-term durability of Cortrophin Gel against potential generic competition due to complex formulation and strong IP protections.
• M&A Strategy: The company is exploring opportunities to expand its Rare Disease business but is focused on making the right strategic acquisitions rather than rushing into deals.

Overall, ANI Pharmaceuticals reported a strong quarter with significant growth in revenues and EBITDA, particularly from its Rare Disease segment, while also navigating challenges in its Retina portfolio and anticipating competitive pressures in the Generics market.